Home Featured Page 187

Featured

Latest

Psilocybin for Cocaine Use Disorder: Peter Hendricks on a Trial Ten Years in the Making

Pα+ Psychedelic Bulletin #224: Reactions to Trump’s Psychedelics Executive Order, and What Comes Next; Pre-EO, DEA Poured Cold Water on Right to Try

God, Gabon, and Government: W. Bryan Hubbard on Ibogaine, the Executive Order, and What Comes Next

The Optimisation Problem: What Bryan Johnson’s 5-MeO-DMT Experiment Reveals About Psychedelics Going Mainstream

MindMed Appoints Francois Lilienthal, MD as Chief Commercial Officer

PT307 – Kathryn L. Tucker, JD – The Right to Try...

Health Canada Approves First Special Access Program Requests for Psilocybin

Psychedelic Bulletin: Bizarre News from Across the Psychedelics Space (April 1,...

Canada’s SAP Expansion Signals a Step Forward for Psychedelics

PT306 – Dr. Devon Christie – Vital Psychedelic Conversations

Mydecine Reports Financial Results for the Fiscal Year 2021 and Provides...

Silo Pharma Enters into Agreement with Contract Research Organization for Pharmacokinetic...

Cybin Announces Initiation of Kernel Flow® Feasibility Study Measuring Psychedelic Effects...

Mydecine Innovations Group Announces Closing of First Tranche Under Share Subscription...

EDITOR PICKS

Psilocybin for Cocaine Use Disorder: Peter Hendricks on a Trial Ten...

Pα+ Psychedelic Bulletin #224: Reactions to Trump’s Psychedelics Executive Order, and...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.